jRCT2080222241已完成3 期
-
Sandoz.K.K1 个研究点目标入组 618 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 618
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- A Randomized, Controlled, Double-blind Phase Iii Trial
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Patient with previously untreated advanced stage, CD20-positive FL
- •>= 18 years old
- •Patient with ECOG performance status 0, 1 or 2.
排除标准
- •Exclusion Criteria:
- •Patient who has previously received any prior therapy for lymphoma
- •Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).
- •Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
-
efficacy efficacy
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...